Press release

Centre Hospitalier de l’Université de Montréal (CHUM) partners with A.I. VALI to evaluate an artificial intelligence platform for real-time endoscopy image analysis

October 12, 2023

October 12, 2023 (Toronto, ON) – Currently, clinicians go through a time-consuming process of manually analyzing endoscopy video and images, and then reporting the patient’s results. The process can sometimes lead to unfortunate human errors. This is exacerbated by the current backlog of patients waiting for endoscopies resulting in increased physician burnout.

Through its Early Adopter Health Network (EAHN™), OBIO® has facilitated the first-ever partnership between the Centre Hospitalier de l’Université de Montréal (CHUM) and A.I. VALI, a female-led, Toronto-based health technology start-up, to evaluate the modular Artificial intelligence (AI) platform, AIDREA™, within endoscopy clinics.

The A.I. VALI AIDREA™ platform uses real-time Machine Learning (ML) and Deep Learning (DL) techniques to analyze physicians’ voices during procedures, as well as data collected from medical images, such as endoscopy video images and tissue biopsy samples. This solution provides clinicians with accurate, reproducible and affordable real-time analysis. It has a critical impact on the quality of analysis in the early detection of diseases such as cancer and allows delivery of the best-personalized treatment model. The AIDREA™ solution offers four key features: it works with any endoscopy device, it provides real-time video image analysis, it generates instant patient reports, and it has a feedback loop to train the AI model.

“Our mission is to improve the quality of diagnosis and care, therefore, validating the AIDREA™ platform in top Canadian research hospital settings benefits A.I. VALI by providing valuable feedback, enhancing credibility, opening new market opportunities, acquiring data for research and development, and generating financial gains through increased adoption,” said Azar Azad, CEO of A.I. VALI.

“OBIO is thrilled to support a female-led company that is tackling significant healthcare challenges while simultaneously leveraging critical technologies such as AI,” said Dr. Maura Campbell, President and CEO of OBIO®. “The A.I. VALI platform can help improve workflow efficiencies to address patient backlogs that hospitals are currently facing which in turn can result in increased diagnostic accuracy.”

About OBIO®

OBIO®, a not-for-profit, membership-based organization dedicated to advancing health technology innovation and commercialization, is prioritizing the evaluation of new technologies through their Early Adopter Health Network (EAHN™). OBIO® is engaged in strategy, programming, policy development and advocacy to further the commercialization of human health technologies, positioning Canada as a leader in the international marketplace.

About A.I. VALI 

A.I. VALI offers services in research and development, analytical validation, optimization, and validation for regulatory submissions. These services can be utilized by our clients and incorporated into the early stages of drug development through clinical trials and validation of biomarkers, or companion diagnostics (CDx), by providing precise interpretation of information on cell functioning, as well as the structure of critical proteins and biomarkers. Our extensible data science environment and toolkit was built to serve as an architectural framework and community platform for developing and distributing reusable data visualization modules and reusable multi-modality data integration pipelines. Our innovative system allows our team to develop the algorithms, validate them properly, and either commercialize them directly, or support our clients in their efforts to commercialize these products.


For more information about OBIO’s Early Adopter Health Network (EAHN™), or if you are interested in joining the Network, please contact:

Bibaswan Ghoshal
Senior Director, Technology Adoption
Ontario Bioscience Innovation Organization

For more information about A.I. VALI please contact:

Azar Azad

For any additional questions, please contact us.